Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment

    Access Status
    Fulltext not available
    Authors
    Kong, X.
    Nguyen, N.
    Choi, Y.
    Zhang, Guicheng
    Nguyen, H.
    Filka, E.
    Green, S.
    Yong, W.
    Liau, L.
    Green, R.
    Kaprealian, T.
    Pope, W.
    Nghiemphu, P.
    Cloughesy, T.
    Lassman, A.
    Lai, A.
    Date
    2018
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Kong, X. and Nguyen, N. and Choi, Y. and Zhang, G. and Nguyen, H. and Filka, E. and Green, S. et al. 2018. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. International Journal of Radiation: Oncology - Biology - Physics. 100 (5): pp. 1195-1203.
    Source Title
    International Journal of Radiation: Oncology - Biology - Physics
    DOI
    10.1016/j.ijrobp.2018.01.001
    ISSN
    0360-3016
    School
    School of Public Health
    URI
    http://hdl.handle.net/20.500.11937/74158
    Collection
    • Curtin Research Publications
    Abstract

    © 2018 Elsevier Inc. Purpose: To assess the safety and efficacy of upfront treatment using bortezomib combined with standard radiation therapy (RT) and temozolomide (TMZ), followed by adjuvant bortezomib and TMZ for =24 cycles, in patients with newly diagnosed glioblastoma multiforme (GBM). Methods and Materials: Twenty-four patients with newly diagnosed GBM were enrolled. The patients received standard external beam regional RT with concurrent TMZ beginning 3 to 6 weeks after surgery, followed by adjuvant TMZ and bortezomib for =24 cycles or until tumor progression. During RT, bortezomib was given at 1.3 mg/m2 on days 1, 4, 8, 11, 29, 32, 36, and 39. After RT, bortezomib was given at 1.3 mg/m2 on days 1, 4, 8, and 11 every 4 weeks. Results: No unexpected adverse events occurred from the addition of bortezomib. The efficacy analysis showed a median progression-free survival (PFS) of 6.2 months (95% confidence interval [CI] 3.7-8.8), with promising PFS rates at =18 months compared with historical norms (25.0% at 18 and 24 months; 16.7% at 30 months). In terms of overall survival (OS), the median OS was 19.1 months (95% CI 6.7-31.4), with improved OS rates at =12 months (87.5% at 12, 50.0% at 24, 34.1% at 36-60 months) compared with the historical norms. The median PFS was 24.7 months (95% CI 8.5-41.0) in 10 MGMT methylated and 5.1 months (95% CI 3.9-6.2) in 13 unmethylated patients. The estimated median OS was 61 months (95% CI upper bound not reached) in the methylated and 16.4 months (95% CI 11.8-21.0) in the unmethylated patients. Conclusions: The addition of bortezomib to current standard radiochemotherapy in newly diagnosed GBM patients was tolerable. The PFS and OS rates appeared promising, with more benefit to MGMT methylated patients. Further clinical investigation is warranted in a larger cohort of patients.

    Related items

    Showing items related by title, author, creator and subject.

    • Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model
      Siveen, K.; Mustafa, N.; Li, F.; Kannaiyan, R.; Ahn, K.; Kumar, Alan Prem; Chng, W.; Sethi, G. (2014)
      Multiple myeloma (MM) is a B cell malignancy characterized by clonal proliferation of plasma cells in the bone marrow. With the advent of novel targeted agents, the median survival rate has increased to 5 -7 years. However, ...
    • Short-and long-term survival in treated elderly hypertensive patients with or without diabetes: Findings from the second Australian national blood pressure study
      Chowdhury, E.; Owen, A.; Ademi, Z.; Krum, H.; Johnston, C.; Wing, L.; Nelson, M.; Reid, Christopher (2014)
      Background: We sought to determine the incidence of newly diagnosed diabetes in treated elderly hypertensive patients and the prognostic impact of diabetes on long-term survival. Methods: The Second Australian National ...
    • A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): Study protocol for a randomised controlled trial
      Gunatilake, S.; Brims, Fraser; Fogg, C.; Lawrie, I.; Maskell, N.; Forbes, K.; Rahman, N.; Morris, S.; Ogollah, R.; Gerry, S.; Peake, M.; Darlison, L.; Chauhan, A. (2014)
      Background: Malignant pleural mesothelioma is an incurable cancer caused by exposure to asbestos. The United Kingdom has the highest death rate from mesothelioma in the world and this figure is increasing. Median survival ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.